X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs BIOCON LTD - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD BIOCON LTD STRIDES SHASUN LTD/
BIOCON LTD
 
P/E (TTM) x 14.0 36.6 38.2% View Chart
P/BV x 1.9 4.9 38.9% View Chart
Dividend Yield % 0.6 1.5 36.2%  

Financials

 STRIDES SHASUN LTD   BIOCON LTD
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-16
BIOCON LTD
Mar-16
STRIDES SHASUN LTD/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,413496 285.0%   
Low Rs848397 213.9%   
Sales per share (Unadj.) Rs353.3174.3 202.7%  
Earnings per share (Unadj.) Rs23.444.8 52.2%  
Cash flow per share (Unadj.) Rs41.056.9 72.0%  
Dividends per share (Unadj.) Rs5.005.00 100.0%  
Dividend yield (eoy) %0.41.1 39.5%  
Book value per share (Unadj.) Rs320.4202.8 158.0%  
Shares outstanding (eoy) m89.35200.00 44.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.22.6 125.0%   
Avg P/E ratio x48.310.0 485.4%  
P/CF ratio (eoy) x27.67.8 351.8%  
Price / Book Value ratio x3.52.2 160.3%  
Dividend payout %21.411.2 191.6%   
Avg Mkt Cap Rs m100,98889,220 113.2%   
No. of employees `0004.74.4 106.2%   
Total wages/salary Rs m4,9886,363 78.4%   
Avg. sales/employee Rs Th6,730.07,894.5 85.2%   
Avg. wages/employee Rs Th1,063.61,441.2 73.8%   
Avg. net profit/employee Rs Th445.52,029.7 21.9%   
INCOME DATA
Net Sales Rs m31,56434,854 90.6%  
Other income Rs m1,212845 143.5%   
Total revenues Rs m32,77635,699 91.8%   
Gross profit Rs m5,2138,200 63.6%  
Depreciation Rs m1,5732,423 64.9%   
Interest Rs m1,803102 1,767.7%   
Profit before tax Rs m3,0496,520 46.8%   
Minority Interest Rs m127-744 -17.0%   
Prior Period Items Rs m-270-   
Extraordinary Inc (Exp) Rs m-3715,754 -6.4%   
Tax Rs m6892,569 26.8%   
Profit after tax Rs m2,0898,961 23.3%  
Gross profit margin %16.523.5 70.2%  
Effective tax rate %22.639.4 57.3%   
Net profit margin %6.625.7 25.7%  
BALANCE SHEET DATA
Current assets Rs m35,94939,932 90.0%   
Current liabilities Rs m19,40216,276 119.2%   
Net working cap to sales %52.467.9 77.2%  
Current ratio x1.92.5 75.5%  
Inventory Days Days7154 132.4%  
Debtors Days Days12786 147.1%  
Net fixed assets Rs m34,47839,101 88.2%   
Share capital Rs m8941,000 89.4%   
"Free" reserves Rs m22,60138,591 58.6%   
Net worth Rs m28,63240,556 70.6%   
Long term debt Rs m27,45520,724 132.5%   
Total assets Rs m76,59184,816 90.3%  
Interest coverage x2.764.9 4.1%   
Debt to equity ratio x1.00.5 187.7%  
Sales to assets ratio x0.40.4 100.3%   
Return on assets %5.110.7 47.6%  
Return on equity %7.322.1 33.0%  
Return on capital %8.219.0 43.0%  
Exports to sales %48.130.7 156.5%   
Imports to sales %14.520.4 70.9%   
Exports (fob) Rs m15,19210,717 141.8%   
Imports (cif) Rs m4,5657,105 64.2%   
Fx inflow Rs m16,61211,789 140.9%   
Fx outflow Rs m5,2928,393 63.1%   
Net fx Rs m11,3203,396 333.3%   
CASH FLOW
From Operations Rs m7175,264 13.6%  
From Investments Rs m-22,284-9,540 233.6%  
From Financial Activity Rs m29,48810,867 271.3%  
Net Cashflow Rs m8,0736,591 122.5%  

Share Holding

Indian Promoters % 27.7 40.4 68.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 37.8 8.4 450.0%  
FIIs % 8.6 10.7 80.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 19.9 130.2%  
Shareholders   56,241 109,995 51.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare STRIDES SHASUN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Aug 18, 2017 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD - ALEMBIC LTD COMPARISON

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS